Fratelli Beretta USA, Inc. Recalls Mortadella Product Due to Misbranding and Undeclared Allergens

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

WASHINGTON, Feb. 22, 2017 – Fratelli Beretta USA, Inc., a Mount Olive, N.J. establishment, is recalling approximately 468 pounds of mortadella product due to misbranding and undeclared allergens, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced today. The product contains pistachio nuts, known allergens which are not declared on the product label.

The mortadella items were produced on Nov. 30, 2016. The following product is subject to recall:

  • 3-oz. plastic packages containing slices of “Deli Thin Dietz & Watson Mortadella” with Lot# LO23633800 and Best By Date April 2, 2017.  

The product subject to recall bears establishment number “EST. 7543B” inside the USDA mark of inspection. These items were shipped to a distributor in Pennsylvania and further distributed to retail and distribution centers in Arizona, California, Florida, Michigan, Nevada, New Jersey, Oklahoma, Pennsylvania, and Texas.

- Advertisement -

The problem was discovered Feb. 17, 2017 by the Dietz & Watson distributor who observed pistachio nuts through the clear product packaging in a case of products labeled as Deli Thin Dietz & Watson Mortadella products and notified the establishment. The Deli Thin Dietz & Watson Mortadella products are not formulated with pistachio nuts and do not declare the pistachio nut ingredient on the label.

There have been no confirmed reports of adverse reactions due to consumption of these products. Anyone concerned about an injury or illness should contact a healthcare provider.  

Consumers who have purchased these products are urged not to consume them. These products should be thrown away or returned to the place of purchase. 

FSIS routinely conducts recall effectiveness checks to verify recalling firms notify theircustomers of the recall and that steps are taken to make certain that the product is no longer available to consumers. When available, the retail distribution list(s) will be posted on the FSIS website at www.fsis.usda.gov/recalls.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -